Global Clinical Trial Manufacturing Service 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI02260210

Publication Date:

February 21, 2025

Pages:

108

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Clinical Trial Manufacturing Service market size is predicted to grow from US$ 1140 million in 2025 to US$ 1490 million in 2031; it is expected to grow at a CAGR of 4.6% from 2025 to 2031.
Clinical trial manufacturing service is a service that provides customized production for drugs, medical devices and biological products in the clinical trial stage. This service usually includes the entire manufacturing process from raw material procurement, production process design, quality control to packaging and transportation. Clinical trial manufacturing service is designed to meet the special needs of clinical trials for products, such as small batches, multiple batches, and rapid response. Through a professional production team and advanced production equipment, clinical trial manufacturing service can ensure the safety and effectiveness of products while complying with relevant laws and regulations and regulatory requirements. In addition, this service can also provide flexible production solutions and make timely adjustments and optimizations according to the progress and needs of clinical trials. Clinical trial manufacturing service is of great significance to promoting the development of new drugs and improving the quality of clinical trials of medical devices and biological products, and provides strong support for the launch of new drugs and medical innovation.
United States market for Clinical Trial Manufacturing Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Clinical Trial Manufacturing Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Clinical Trial Manufacturing Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Clinical Trial Manufacturing Service players cover SGS, Intertek, Pharmsky, SK pharmteco, Quotient Sciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淐linical Trial Manufacturing Service Industry Forecast鈥� looks at past sales and reviews total world Clinical Trial Manufacturing Service sales in 2024, providing a comprehensive analysis by region and market sector of projected Clinical Trial Manufacturing Service sales for 2025 through 2031. With Clinical Trial Manufacturing Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Clinical Trial Manufacturing Service industry.
This Insight Report provides a comprehensive analysis of the global Clinical Trial Manufacturing Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Clinical Trial Manufacturing Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Clinical Trial Manufacturing Service market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Clinical Trial Manufacturing Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Clinical Trial Manufacturing Service.
This report presents a comprehensive overview, market shares, and growth opportunities of Clinical Trial Manufacturing Service market by product type, application, key players and key regions and countries.
Segmentation by Type:
Phase I Clinical Trial Manufacturing Service
Phase II Clinical Trial Manufacturing Service
Phase III Clinical Trial Manufacturing Service
Segmentation by Application:
Oral Medications
Inhaled Medications
Parenteral Medications
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
SGS
Intertek
Pharmsky
SK pharmteco
Quotient Sciences
UPM Pharmaceuticals
Sharp Services
PCI
NUVISAN
Vetter-Pharma
Lonza
MAC Research
Cambrex
Nanopharm
Patheon

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Clinical Trial Manufacturing Service 麻豆原创 Size (2020-2031)
2.1.2 Clinical Trial Manufacturing Service 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Clinical Trial Manufacturing Service by Country/Region (2020, 2024 & 2031)
2.2 Clinical Trial Manufacturing Service Segment by Type
2.2.1 Phase I Clinical Trial Manufacturing Service
2.2.2 Phase II Clinical Trial Manufacturing Service
2.2.3 Phase III Clinical Trial Manufacturing Service
2.3 Clinical Trial Manufacturing Service 麻豆原创 Size by Type
2.3.1 Clinical Trial Manufacturing Service 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Clinical Trial Manufacturing Service 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Clinical Trial Manufacturing Service Segment by Application
2.4.1 Oral Medications
2.4.2 Inhaled Medications
2.4.3 Parenteral Medications
2.4.4 Others
2.5 Clinical Trial Manufacturing Service 麻豆原创 Size by Application
2.5.1 Clinical Trial Manufacturing Service 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Clinical Trial Manufacturing Service 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Clinical Trial Manufacturing Service 麻豆原创 Size by Player
3.1 Clinical Trial Manufacturing Service 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Clinical Trial Manufacturing Service Revenue by Player (2020-2025)
3.1.2 Global Clinical Trial Manufacturing Service Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Clinical Trial Manufacturing Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Clinical Trial Manufacturing Service by Region
4.1 Clinical Trial Manufacturing Service 麻豆原创 Size by Region (2020-2025)
4.2 Global Clinical Trial Manufacturing Service Annual Revenue by Country/Region (2020-2025)
4.3 Americas Clinical Trial Manufacturing Service 麻豆原创 Size Growth (2020-2025)
4.4 APAC Clinical Trial Manufacturing Service 麻豆原创 Size Growth (2020-2025)
4.5 Europe Clinical Trial Manufacturing Service 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Clinical Trial Manufacturing Service 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Clinical Trial Manufacturing Service 麻豆原创 Size by Country (2020-2025)
5.2 Americas Clinical Trial Manufacturing Service 麻豆原创 Size by Type (2020-2025)
5.3 Americas Clinical Trial Manufacturing Service 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Clinical Trial Manufacturing Service 麻豆原创 Size by Region (2020-2025)
6.2 APAC Clinical Trial Manufacturing Service 麻豆原创 Size by Type (2020-2025)
6.3 APAC Clinical Trial Manufacturing Service 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Clinical Trial Manufacturing Service 麻豆原创 Size by Country (2020-2025)
7.2 Europe Clinical Trial Manufacturing Service 麻豆原创 Size by Type (2020-2025)
7.3 Europe Clinical Trial Manufacturing Service 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Clinical Trial Manufacturing Service by Region (2020-2025)
8.2 Middle East & Africa Clinical Trial Manufacturing Service 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Clinical Trial Manufacturing Service 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Clinical Trial Manufacturing Service 麻豆原创 Forecast
10.1 Global Clinical Trial Manufacturing Service Forecast by Region (2026-2031)
10.1.1 Global Clinical Trial Manufacturing Service Forecast by Region (2026-2031)
10.1.2 Americas Clinical Trial Manufacturing Service Forecast
10.1.3 APAC Clinical Trial Manufacturing Service Forecast
10.1.4 Europe Clinical Trial Manufacturing Service Forecast
10.1.5 Middle East & Africa Clinical Trial Manufacturing Service Forecast
10.2 Americas Clinical Trial Manufacturing Service Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.2.2 Canada 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.2.3 Mexico 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.2.4 Brazil 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.3 APAC Clinical Trial Manufacturing Service Forecast by Region (2026-2031)
10.3.1 China Clinical Trial Manufacturing Service 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.3.3 Korea 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.3.4 Southeast Asia 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.3.5 India 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.3.6 Australia 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.4 Europe Clinical Trial Manufacturing Service Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.4.2 France 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.4.3 UK 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.4.4 Italy 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.4.5 Russia 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.5 Middle East & Africa Clinical Trial Manufacturing Service Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.5.2 South Africa 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.5.3 Israel 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.5.4 Turkey 麻豆原创 Clinical Trial Manufacturing Service Forecast
10.6 Global Clinical Trial Manufacturing Service Forecast by Type (2026-2031)
10.7 Global Clinical Trial Manufacturing Service Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Clinical Trial Manufacturing Service Forecast
11 Key Players Analysis
11.1 SGS
11.1.1 SGS Company Information
11.1.2 SGS Clinical Trial Manufacturing Service Product Offered
11.1.3 SGS Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 SGS Main Business Overview
11.1.5 SGS Latest Developments
11.2 Intertek
11.2.1 Intertek Company Information
11.2.2 Intertek Clinical Trial Manufacturing Service Product Offered
11.2.3 Intertek Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Intertek Main Business Overview
11.2.5 Intertek Latest Developments
11.3 Pharmsky
11.3.1 Pharmsky Company Information
11.3.2 Pharmsky Clinical Trial Manufacturing Service Product Offered
11.3.3 Pharmsky Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Pharmsky Main Business Overview
11.3.5 Pharmsky Latest Developments
11.4 SK pharmteco
11.4.1 SK pharmteco Company Information
11.4.2 SK pharmteco Clinical Trial Manufacturing Service Product Offered
11.4.3 SK pharmteco Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 SK pharmteco Main Business Overview
11.4.5 SK pharmteco Latest Developments
11.5 Quotient Sciences
11.5.1 Quotient Sciences Company Information
11.5.2 Quotient Sciences Clinical Trial Manufacturing Service Product Offered
11.5.3 Quotient Sciences Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Quotient Sciences Main Business Overview
11.5.5 Quotient Sciences Latest Developments
11.6 UPM Pharmaceuticals
11.6.1 UPM Pharmaceuticals Company Information
11.6.2 UPM Pharmaceuticals Clinical Trial Manufacturing Service Product Offered
11.6.3 UPM Pharmaceuticals Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 UPM Pharmaceuticals Main Business Overview
11.6.5 UPM Pharmaceuticals Latest Developments
11.7 Sharp Services
11.7.1 Sharp Services Company Information
11.7.2 Sharp Services Clinical Trial Manufacturing Service Product Offered
11.7.3 Sharp Services Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Sharp Services Main Business Overview
11.7.5 Sharp Services Latest Developments
11.8 PCI
11.8.1 PCI Company Information
11.8.2 PCI Clinical Trial Manufacturing Service Product Offered
11.8.3 PCI Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 PCI Main Business Overview
11.8.5 PCI Latest Developments
11.9 NUVISAN
11.9.1 NUVISAN Company Information
11.9.2 NUVISAN Clinical Trial Manufacturing Service Product Offered
11.9.3 NUVISAN Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 NUVISAN Main Business Overview
11.9.5 NUVISAN Latest Developments
11.10 Vetter-Pharma
11.10.1 Vetter-Pharma Company Information
11.10.2 Vetter-Pharma Clinical Trial Manufacturing Service Product Offered
11.10.3 Vetter-Pharma Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Vetter-Pharma Main Business Overview
11.10.5 Vetter-Pharma Latest Developments
11.11 Lonza
11.11.1 Lonza Company Information
11.11.2 Lonza Clinical Trial Manufacturing Service Product Offered
11.11.3 Lonza Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Lonza Main Business Overview
11.11.5 Lonza Latest Developments
11.12 MAC Research
11.12.1 MAC Research Company Information
11.12.2 MAC Research Clinical Trial Manufacturing Service Product Offered
11.12.3 MAC Research Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 MAC Research Main Business Overview
11.12.5 MAC Research Latest Developments
11.13 Cambrex
11.13.1 Cambrex Company Information
11.13.2 Cambrex Clinical Trial Manufacturing Service Product Offered
11.13.3 Cambrex Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Cambrex Main Business Overview
11.13.5 Cambrex Latest Developments
11.14 Nanopharm
11.14.1 Nanopharm Company Information
11.14.2 Nanopharm Clinical Trial Manufacturing Service Product Offered
11.14.3 Nanopharm Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Nanopharm Main Business Overview
11.14.5 Nanopharm Latest Developments
11.15 Patheon
11.15.1 Patheon Company Information
11.15.2 Patheon Clinical Trial Manufacturing Service Product Offered
11.15.3 Patheon Clinical Trial Manufacturing Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Patheon Main Business Overview
11.15.5 Patheon Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.